Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Receivables - Accured (2024 - 2025)

PharmaCyte Biotech (PMCB) has disclosed Receivables - Accured for 2 consecutive years, with $287500.0 as the latest value for Q4 2025.

  • Quarterly Receivables - Accured changed N/A to $287500.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $287500.0 through Oct 2025, changed N/A year-over-year, with the annual reading at $137500.0 for FY2025, 0.0% changed from the prior year.
  • Revenue - Other for Q2 2016 was $9025.0 at PharmaCyte Biotech, up from $1180.0 in the prior quarter.
  • The five-year high for Receivables - Accured was $287500.0 in Q4 2025, with the low at $137500.0 in Q2 2024.